Nuran Wireless Products Chosen for Clinical Trials

Nuran Wireless (CSE:NUR) announces that its GMS SuperFemto and LiteCell solutions continue to be chosen for clinical trials across six countries and four continents.
According to the press release:

NuRAN’s GSM LiteCell is a low-power (54W) and low operating expense (“OPEX”) GSM base station designed specifically for use in rural, low-density and lower average revenue per user (“ARPU”) urban areas.
NuRAN’s GSM LiteCell has already been deployed in North and South America (including Mexico), Europe, Africa and Asia where it has given rural communities network coverage for the very first time.
It is now being trialled by a number of additional operators and community organisations in South America and Africa providing voice coverage to villages in rural areas not currently covered by any kind of voice or data network as well as in urban areas where there are still opportunities to provide an affordable service to lower ARPU customers. Successful trials would convert into hundreds of units in the next coming months.
NuRAN’s GSM-EDGE Superfemto can be deployed separately from GSM LiteCell to provide coverage in remote areas.  Applications include in-building coverage, offshore platforms and ships, private networks.
According to GSMA Intelligence, 2G technology still accounts for 58.5 per cent of the world’s 7.11 billion mobile connections, compared to 32.5 per cent for 3G and 9 per cent for 4G. The analyst house expects 2G technology to maintain global market dominance.

Click here to read the full press release from NuRAN.